SPIMACO signs an agreement with GSK:

05/11/2013 Argaam

SPIMACO Pharmaceutical Company announced today on tadawul signing 5 years renewable agreement with Glaxo SmithKline Company (GSK) to market and distribute Respira product (Asthma treatment) in the Kingdom.

Respira is expected to be offered in the local markets during the first half of 2014 and expected to generate SAR 150m sales revenues per annum to SPIMACO.

.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.